CrowdStrike Holdings Bolsa (NASDAQ: CRWD)

Últimas noticias sobre CrowdStrike Holdings (NASDAQ:CRWD) Bolsa

CROWDSTRIKE HOLDINGS INC - A

CrowdStrike Holdings

CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.

CrowdStrikeKirkland,,Washington, - ,Usa,-,December,10,2019:,"crowdstrike",Sign

News

Movers

CRWD

CrowdStrike decepciona en ingresos y previsiones, pese a buenos beneficios y fuerte impulso en ciberseguridad basada en IA.

CrowdStrike cae tras resultados mixtos y previsiones por debajo del consenso

Dollar Tree

Earnings

Equities

DLTR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: DLTR, CRWD, THO, HPE y PVH.

5 acciones en el foco este miércoles: DLTR, CRWD, THO, HPE y PVH

Screenshot,Of,Buying,Male,Stocks,And,Futures,Markets,In,Thailand

Markets

$BTC

CRWV

HOOD

NVDA

Los mercados bursátiles de Estados Unidos cerraron en terreno positivo ayer, con el índice Nasdaq ganando más de 150 puntos, un alza del 0,8 %, hasta los 19.398,86 puntos. El S&amp;P 500 avanzó un 0,58 % y terminó en 5.970,37, mientras que el Dow Jones sumó un 0,5 %, cerrando en 42.519,64.

CoreWeave, Nvidia, Wells Fargo, CrowdStrike, Robinhood: 5 valores que están en el radar de los inversores

Comprehensive offering will enable public safety agencies to adhere to new federal reporting requirements
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tylertech.com%2F&amp;esheet=54297529&amp;newsitemid=20250728949755&amp;lan=en-US&amp;anchor=Tyler+Technologies%2C+Inc.&amp;index=1&amp;md5=520d1dc442ffbffc1826bd2264c8eb06">Tyler Technologies, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) announced today that it has acquired Emergency Networking, Inc., a software-as-a-service (SaaS) company specializing in cloud-native software for fire departments and emergency medical services (EMS) agencies.
Tyler's acquisition of Emergency Networking strengthens Tyler's comprehensive public safety suite at a critical time. By January 1, 2026, all fire and EMS departments nationwide must move from the National Fire Incident Reporting System (NFIRS) to the National Emergency Response Information System (NERIS). Emergency Networking is one of the first fire records reporting solutions to meet and submit to the new NERIS compliance requirements.
With Emergency Networking's expertise in the fire and EMS industry, Tyler now has the most comprehensive suite of solutions for public safety agencies, from law enforcement to first responders to EMS agencies.

Tyler Technologies Acquires Emergency Networking To Support Nationwide Shift To NERIS Compliance By 2026; No Financial Terms Disclosed

Think you and your spouse are crushing it financially? You might be doing better than you think — or not even close — depending on how you measure.
According to personal finance site <a href="https://www.financialsamurai.com/the-average-net-worth-for-the-above-average-married-couple/">Financial Samurai</a>, there's a big difference between being typical and being intentional. The site's benchmark for the "above-average person" doesn't come from ambition or vibes — it's built on clear expectations.
To be considered above average, you're expected to graduate from college, which only about 36% of Americans do. You're expected to work diligently, save consistently, take full advantage of retirement accounts like 401(k)s or IRAs, track your finances, invest regularly, live within your means, and expect nothing from your parents, spouse, or the government.
Don't Miss:
<ul class="wp-block-list">
<li>Be part of the breakthrough that could replace plastic as we know it—<a href="https://www.benzinga.com/money/timeplast-advertorial">invest in Timeplast before the July 31st deadline and help revolutionize a $1.3T industry.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
In short, if you're living like a C-student but expecting an A-lifestyle, Financial Samurai would not put you in the above-average category.
Based on this profile, an above-average individual is projected to reach a net worth of around $660,250 by age 45. But what if there are two of you?
<h2 class="wp-block-heading">Defining the Above-Average Couple</h2>
Some might assume that two financially savvy individuals should simply double their solo benchmarks and call it a day. But Financial Samurai recommends a more conservative approach by using a 1.7x multiplier instead of 2. This accounts for the financial efficiencies that couples often enjoy when it comes to housing, utilities, food, insurance, and transportation.
By applying this method, an above-average couple in their mid-40s should aim for a combined net worth of roughly $1.12 million.
That target represents a couple who's aligned on money, disciplined with spending, and working toward common long-term goals. This isn't a figure reserved for doctors and tech executives — it's within reach for many dual-income households that save and invest consistently over time.
Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora &amp; MGM—<a href="https://www.benzinga.com/money/rad-intel">Just $0.63 Before NASDAQ Launch</a>
<h2 class="wp-block-heading">Where Does That Put You Nationally?</h2>
The Federal Reserve's most recent <a href="https://www.federalreserve.gov/publications/files/2023-report-economic-well-being-us-households-202405.pdf">Survey of Consumer Finances</a> reports that the median net worth for U.S. households is around $192,900. That means half of American households are below that figure. The average net worth, skewed by ultra-high earners, is higher — roughly $1.06 million.
If you're aiming for the top 10% of households, the bar is significantly higher. To join the top decile in America, you need a <a href="https://www.benzinga.com/personal-finance/24/12/42675663/think-youre-richer-than-your-peers-heres-the-net-worth-you-need-to-rank-among-the-top-10-for-your-age">household net worth</a> of at least $1.92 million. To break into the top 5%, you'll need around $3.78 million. The top 1% of households starts at approximately $13.7 million.
By comparison, a Financial Samurai–style above-average couple may not be in the top 10% just yet — but they're still well ahead of most American households.
<h2 class="wp-block-heading">Why Couples Have the Advantage</h2>
Financially aligned couples often benefit from the natural efficiencies of sharing a household. Two people working together toward shared savings and investing goals can make faster progress than individuals operating separately. When couples reduce overlapping costs and increase financial communication, they compound their efforts — both literally and figuratively.
<a href="https://www.benzinga.com/personal-finance/25/02/43447772/can-you-guess-what-it-takes-to-be-a-rich-household-heres-the-income-youll-need-to-be-in-the-top-1">Income alone</a> isn't what separates average from above-average. Behavior, consistency, and clarity do. Financial Samurai emphasizes the importance of tracking net worth regularly, resisting lifestyle creep, and prioritizing long-term goals over short-term indulgences.
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
If your household net worth is between $500,000 and $1 million, you're likely ahead of the national average but not yet in the top 10%. If you've crossed the $1.9 million threshold in your 40s or 50s, you're solidly within the wealthiest tier of U.S. households.
<h2 class="wp-block-heading">Graded on a Curve? Not Quite</h2>
"Above average" sounds like something you'd see on a report card — but real-life finances aren't graded on a curve. One couple's $1.2 million might mean financial freedom. For another, it barely covers the mortgage and daycare.
Some want to upgrade their home. Others want to backpack through Europe. The point is: there's no universal benchmark.
If you're living below your means, investing in a way that fits your risk level, and <a href="https://www.benzinga.com/money/smartasset">consistently working toward goals</a> that matter to you, you're probably doing just fine.
There's no gold star for hitting a number. The only standard that counts is the one you set together.
Read Next: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Image: Shutterstock

Personal Finance

Are You an 'Above‑Average' Couple? Here's The Net Worth You Need to Be Richer Than 90% of Households

CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) on Monday shared 32-week data from the Extension phase of its Phase 2b RewinD-LB trial evaluating oral neflamapimod in patients with <a href="https://www.benzinga.com/general/health-care">Dementia with Lewy Bodies (DLB)</a>.
The initial 16-week, randomized, double-blind, placebo-controlled portion of the study included 159 DLB patients and was followed by a 32-week Extension phase in which all participants received neflamapimod (40mg TID).
Results from the Extension phase showed that neflamapimod continued to slow disease progression and impacted a key plasma marker of neurodegeneration in DLB patients.
Also Read: <a href="https://www.benzinga.com/25/03/44312894/cervomeds-dementia-studys-16-week-data-compelling-enough-to-move-from-sidelines-analyst-says" target="_blank" rel="noreferrer noopener">CervoMed&#8217;s Dementia Study&#8217;s 16-Week Data &#8216;Compelling Enough To Move From Sidelines&#8217; Analyst Says</a>
New Data: 32-Week Results from the Extension Phase of the Phase 2b RewinD-LB Trial1
<ul class="wp-block-list">
<li>An older batch of neflamapimod capsules was utilized, which were associated with plasma exposures below the expected and targeted range, while capsules from a new batch of neflamapimod were associated with achieving target plasma concentrations and observing statistically <a href="https://www.benzinga.com/pressreleases/25/07/g46655323/cervomed-announces-32-week-data-from-rewind-lb-trial-extension-phase-showing-neflamapimods-sustain" target="_blank" rel="noreferrer noopener">significant clinical benefit</a>.</li>
<li>Patients treated with New Capsules demonstrated statistically significant slowed disease progression compared to patients treated with Old Capsules.</li>
<li>Even greater risk reductions were observed in patients with ptau181 &lt; 2.2 pg/mL – the threshold CervoMed believes is the optimal ptau181 threshold for evaluating the presence of AD co-pathology in patients with DLB.</li>
<li>Researchers also presented data evaluating different cut-off levels of ptau181 based on the 32-week results and assessed the correlation between ptau181 and ptau217, a validated biomarker for AD.</li>
</ul>
New Data: Reduction in Plasma Levels of Glial Fibrillary Acidic Protein at Week 32 of Extension Phase
<ul class="wp-block-list">
<li>At Week 32 of the Extension phase, there was a statistically significant reduction from baseline in GFAP plasma levels in patients who received New Capsules for all 32 weeks, with a mean change of -18.4±4.0 pg/mL in all participants (N=107) and -21.2±4.4 pg/mL in participants with screening plasma ptau181 below 2.2 pg/mL (N=91).</li>
<li>Placebo recipients in the initial, double-blind phase of the trial had a mean increase from baseline to Week 16 of +1.1±3.0 pg/mL in all participants (N=74) and +1.1±3.3 pg/mL in the subset with screening plasma ptau181 below 2.2 pg/mL (N=65).</li>
</ul>
Both Old and New Capsules demonstrated comparable tolerability profiles, and no new safety signals were identified during the Extension phase of the trial.
During the first 16 weeks of the Extension phase, a lower incidence of falls was seen in participants with screening ptau181 &lt; 2.2 pg/mL who received New Capsules of neflamapimod as compared to participants who received either Old Capsules or placebo (vs. Old Capsules, p=0.025; vs. placebo, p=0.007).
Price Action: CRVO stock is up 29.4% at $11.62 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46657104/mara-cleanspark-avoided-the-ai-hype-and-thats-their-superpower" target="_blank" rel="noreferrer noopener">MARA, CleanSpark Avoided The AI Hype—And That&#8217;s Their Superpower</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Trading Ideas

General

CRVO

CervoMed's Dementia Data Show Slowed Disease Progression

Financing

NITO

N2OFF Says On July 25, Enters Amendment To Purchase Agreement With YA II PN; Investor Commits To Advance $3M To N2OFF, And Investor Agree To Revise Promissory Notes

SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>), a leading e-commerce platform for residential real estate transactions, today announced that it intends to convene and then adjourn the Special Meeting of Stockholders (the "Special Meeting") scheduled to occur at 9:30 a.m. Pacific Time, on Monday, July 28, 2025 until August 27, 2025. No other business will be conducted at the Special Meeting.
The Special Meeting was being held to consider two proposals related to a discretionary reverse stock split of the Company's common stock. Approval of the proposals does not mean that a reverse stock split would occur. Rather, an approval would provide the Company's Board of Directors with an option to pursue a reverse stock split only if the Board believes it is in the best interests of Opendoor and its stockholders, which includes seeking to ensure that Opendoor remains listed on Nasdaq.
As previously disclosed, the Company received notice from Nasdaq in May that it had failed to comply with Nasdaq listing rules because the closing price of the Company's common stock was below $1.00 per share for 30 consecutive business days.
For Opendoor to be back in compliance with Nasdaq listing rules, the closing price of Opendoor's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days by November 24, 2025, and Nasdaq, in its sole discretion, can extend this minimum 10-day trading period. As of today, Nasdaq has not notified the Company that it has regained compliance with Nasdaq listing requirements.
In light of the recent volatility in the trading of Opendoor's common stock and the impact on its trading price, the Board believes it is in the best interests of Opendoor and its stockholders to adjourn the Special Meeting today to allow for additional time to assess market conditions and the Company's stock price before holding the Special Meeting.
The Special Meeting will be adjourned until 9:30 a.m. Pacific Time on August 27, 2025. It will continue to be held online at <a href="http://www.virtualshareholdermeeting.com/OPEN2025SM">www.virtualshareholdermeeting.com/OPEN2025SM</a>. For information on how to attend the reconvened Special Meeting online and submit questions during the Special Meeting, please see the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the "SEC") on June 16, 2025 (the "Proxy Statement").
The record date for stockholders entitled to vote at the Special Meeting remains June 4, 2025. During the period of adjournment, the Company will continue to accept stockholder votes and any stockholders who have not yet voted are encouraged to do so. The Company encourages any eligible stockholder that has not yet voted their shares or provided voting instructions to their broker or other record holders to do so promptly. Any stockholders who have already voted or submitted a proxy do not need to take any further action unless they wish to change their vote.
Additional Information and Where to Find It
The Company has, on June 16, 2025, filed a Proxy Statement with the SEC with respect to its solicitation of proxies for the Special Meeting.
INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY THE COMPANY AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SOLICITATION.
Investors and security holders may obtain copies of these documents and other documents filed with the SEC by the Company free of charge through the website maintained by the SEC at <a href="http://www.sec.gov/">www.sec.gov</a>. Copies of the documents filed by the Company are also available free of charge by accessing the Company's website at <a href="https://www.globenewswire.com/Tracker?data=smfQXwH-VRSaHCTz5wj0wU93NRllb0R3YkmnycxIUNq6gZuZhNwGhV2ootMScegW7P_1pqN1yAReunfBHoxo_wUhPKQlslmXmrk_RDh1ieM=">www.opendoor.com</a>.

OPEN

Reported Earlier: Opendoor Technologies Intends To Convene And Then Adjourn The Special Meeting Of Stockholders To August 27, 2025

WIIM

RDZN

Roadzen shares are trading lower after the company announced the pricing of a $2.25 million registered direct offer of 1,730,769 shares at $1.30 per share.

TSLA

Tesla shares are trading higher after the company announced a $16.5 billion AI chips deal with Samsung.

PFSA

CORRECTION: Profusa Entered Securities Purchase Agreement With Ascent Partners On Monday July 21, 2025

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 13.4%. Currently, Graphic Packaging Holding has a market capitalization of $7.04 billion. 
Buying $100 In GPK: If an investor had bought $100 of GPK stock 15 years ago, it would be worth $646.92 today based on a price of $23.32 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753715720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Graphic Packaging Holding 15 Years Ago Would Be Worth This Much Today

Enterprise Products Partners L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) on Monday reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46655378/enterprise-reports-second-quarter-2025-earnings" rel="noreferrer noopener">second-quarter 2025</a> earnings that beat analyst expectations on earnings per share but missed on revenue, while setting multiple operating volume records across its midstream network.
Enterprise posted earnings of 66 cents per unit, up 3% from 64 cents in the same quarter a year earlier and beating the consensus estimate of 64 cents. However, revenue came in at $11.36 billion, missing analysts&#8217; expectations of $14.19 billion.
Distributable cash flow (DCF) rose 7% year over year to $1.9 billion, providing 1.6 times coverage of the company&#8217;s declared $0.545 per-unit distribution, up 3.8% from a year ago. Enterprise retained $748 million of DCF to reinvest in growth.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46653030/enterprise-products-partners-gears-up-for-q2-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" target="_blank" rel="noreferrer noopener">Enterprise Products Partners Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Adjusted cash flow from operations remained steady at $2.1 billion, and for the 12 months ended June 30, stood at $8.6 billion. Enterprise repurchased $110 million worth of common units during the quarter and reported a 12-month payout ratio of 57%.
&#8220;In a seasonally weaker quarter challenged by macroeconomic and commodity headwinds, Enterprise reported solid earnings and cash flow,&#8221; said A. J. &#8220;Jim&#8221; Teague, co-chief executive officer of Enterprise&#8217;s general partner.
<h2 class="wp-block-heading">Operating Records and Segment Highlights</h2>
Despite broader market challenges, the company set five new operating records:
<ul class="wp-block-list">
<li>Natural gas processing inlet volumes: 7.8 billion cubic feet per day (Bcf/d), up 3% year over year</li>
<li>Natural gas pipeline volumes: 20.4 trillion Btus per day (TBtus/d), up 9%</li>
<li>Crude oil pipeline volumes: 2.6 million barrels per day (BPD), a new high</li>
<li>Refined products and petrochemical pipelines: 1.0 million BPD</li>
<li>Total NGL pipeline volumes: 4.6 million BPD, up 5%</li>
</ul>
Gross operating margin rose to $2.5 billion, up from $2.4 billion in the prior year&#8217;s quarter.
<ul class="wp-block-list">
<li>NGL Pipelines &amp; Services held flat at $1.3 billion, with higher pipeline and terminal volumes offsetting lower NGL marketing and Rockies processing margins.</li>
<li>Natural Gas Pipelines &amp; Services surged 42% to $417 million, driven by stronger marketing margins, increased Permian volumes, and higher throughput on the Texas Intrastate System.</li>
<li>Crude Oil Pipelines &amp; Services fell to $403 million from $417 million, with lower marine terminal volumes and marketing activity partially offset by lower costs and storage revenues.</li>
<li>Petrochemical &amp; Refined Products slipped to $354 million from $392 million due to weaker octane enhancement margins, though pipeline volumes hit a record.</li>
</ul>
Enterprise reaffirmed that approximately $6 billion in organic growth projects will enter service in the second half of 2025. These include:
<ul class="wp-block-list">
<li>Two new Permian gas processing plants, Mentone West 1 and Orion, boosting processing capacity across the Delaware and Midland Basins to over 4.4 Bcf/d.</li>
<li>Commissioning of the Neches River Terminal in mid-July, with a 120,000 BPD ethane refrigeration train now operational.</li>
<li>Frac 14 and the Bahia NGL pipeline, scheduled to come online in Q4.</li>
</ul>
Enterprise invested $1.3 billion in the second quarter of 2025, including $1.2 billion in growth capital and $117 million in sustaining capex.
The company reaffirmed full-year 2025 organic growth capex guidance of $4.0 billion to $4.5 billion and $525 million in sustaining expenditures.
As of June 30, the company had total debt of $33.1 billion and consolidated liquidity of $5.1 billion, including credit capacity and unrestricted cash.
Price Action: EPD shares are trading lower by 1.38% to $31.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/commodities/25/07/46655853/rare-earths-are-the-energy-transitions-hidden-bottleneck-study-shows" target="_blank" rel="noreferrer noopener">Rare Earths Are The Energy Transition&#8217;s Hidden Bottleneck, Study Shows</a></li>
</ul>
Photo by sdf_qwe via Shutterstock

Enterprise Products Partners Posts Strong Cash Flow, Reaffirms Capex Plan

IPOs

Figma IPO Price Expected Between $30 And $32 Per Share

Rumors

Analyst Ratings

Watching Samsara; Shares See Volume To The Upside, Traders Circulate Stock Picked As A Buy On Popular Trading Newsletter

Biotechnology firms are increasingly turning to innovative combination therapies to <a href="https://www.benzinga.com/general/biotech">tackle hard-to-treat cancers</a>, with promising results sparking investor interest. AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
The study is evaluating Ampligen (rintatolimod) in combination with AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), in metastatic pancreatic cancer patients with <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noopener">stable disease following FOLFIRINOX treatment</a>.
The DURIPANC study, a collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands, is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion.
As of the mid-year report, 14 subjects had been enrolled in DURIPANC. The primary objective of the study is to determine the clinical benefit rate of the combination therapy; the secondary/exploratory objectives include assessing overall survival (OS), progression-free survival (PFS), and initiating immune monitoring using available tissue biopsies <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46657801/aim-immunotech-reports-positive-mid-year-safety-and-efficacy-data-from-phase-2-study-evaluating-am" rel="noreferrer noopener">and peripheral immune profiling</a>.
Following FOLFIRINOX, maintenance or second-line immunotherapies have historically shown limited survival benefit in comparison trials. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS:
<ul class="wp-block-list">
<li>No significant toxicity, an encouraging safety profile for a post-chemo setting.</li>
<li>Around 21% of patients have progression-free survival (PFS) of over 6 months (3/14), with an additional 21% not yet progressed.</li>
<li>The majority (64%) of eligible patients had an overall survival of over 6 months, which is better than expected in this setting.</li>
</ul>
AIM has developed an intellectual property plan specific to pancreatic cancer that includes a recently issued U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection to Aug. 9, 2039.
AIM Price Action: AIM ImmunoTech shares were up 36.79% at $11.49 at the time of publication on Monday<a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">, according to Benzinga Pro data.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46657284/palantirs-next-stop-is-200-says-jim-cramer-as-pltr-glides-like-a-knife-through-butter" target="_blank" rel="noreferrer noopener">Palantir&#8217;s Next Stop Is $200, Says Jim Cramer As PLTR Glides &#8216;Like A Knife Through Butter&#8217;</a></li>
</ul>
Photo: jittawit21/Shutterstock

Why Is Micro-Cap AIM ImmunoTech Stock Surging?

On July 21, 2025, Impact BioMedical Inc. (the "Company" or "Borrower") entered into a Debt Conversion Agreement with DSS, Inc. ("DSS" or "Lender"), pursuant to that certain loan made on March 31, 2023, by the Lender in the form of a revolving promissory note in the original amount of $12,000,000 (the "Original Note"), which was amended on January 18, 2024 to (i) extend the maturity date of the Loan to September 30, 2023, (ii) eliminate any advance feature under the terms of the Original Note, (iii) establish specific repayment terms of the Loan balance, and (v) to amend the interest rate to a market rate of interest (WSJ Prime + 0.5%).
&nbsp;
In connection with the above, the Company and DSS have agreed to settle the outstanding Debt owed to DSS, in which the Borrower shall issue to the Lender 31,939,778 shares of freely tradeable common stock of the Company, par value $0.001 per share (the "Shares") in full and final satisfaction of the Original Note and any amendments thereto and all amounts owed thereunder as of the closing of the transaction, and any and all additional financial or operations support, credit, or services extended by the Lender of its affiliates to Borrower between June 21, 2025 and the transaction closing date.
&nbsp;
The foregoing summary of the terms of the Debt Conversion Agreement is qualified in its entirety by reference to the text of the Debt Conversion Agreement, which is filed hereto as Exhibit 10.1 and is incorporated herein by reference.

Impact BioMedical Says On July 21, 2025, Co Converted $12M Debt To Equity With DSS Through Issuance Of 31.9M Shares

Raymond James analyst Brian MacArthur maintains Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) with a Outperform and raises the price target from $67 to $69.

Price Target

Raymond James Maintains Outperform on Newmont, Raises Price Target to $69

HYPD

Hyperion DeFi shares are trading higher after the company announced it acquired an additional 108,594 HYPE tokens.

Raymond James analyst Wilma Burdis initiates coverage on Blue Owl Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWL#NYSE">OWL</a>) with a Market Perform rating.

Initiation

Raymond James Initiates Coverage On Blue Owl Capital with Market Perform Rating

ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) shares are moving lower Monday after the company announced a 1-for-20 <a href="https://www.benzinga.com/pressreleases/25/07/b46656412/chargepoint-announces-reverse-stock-split">reverse stock split</a>.
What Happened: ChargePoint on Monday implemented a reverse stock split of its common stock on a 1-for-20 basis aimed at increasing the company&#8217;s stock price in order to comply with rules for continued listing on the New York Stock Exchange.
The stock split, which was approved by shareholders on July 8, resulted in every 20 shares of ChargePoint common stock being converted into one share of common stock. The split went into effect on Monday. 
<h3 class="wp-block-heading">How To Buy CHPT Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in ChargePoint&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
CHPT Price Action: <a href="http://benzinga.com/quote/CHPT">ChargePoint stock</a> was halted for volatility in early trading Monday. ChargePoint shares were down 14.5% at $10.44 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46654974/tesla-fans-flocked-from-thousands-of-miles-away-to-ride-robotaxis-during-last-months-austin-launch-i-was-just-speechless">Tesla Fans Flocked From Thousands Of Miles Away To Ride Robotaxis During Last Month&#8217;s Austin Launch: &#8216;I Was Just Speechless&#8217;</a></li>
</ul>
Photo: YuniqueB/Shutterstock.com

Stock Split

CHPT

What's Going On With ChargePoint Stock Today?

Shares of Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) are trading flat Monday morning as investors digest a week that saw the stock hit a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46635102/palantir-technologies-stock-hits-a-new-all-time-high-whats-driving-the-action">new all-time high</a>. The data analytics firm&#8217;s stock capped a week of major gains on Friday, closing at a record high after hitting $160.39 intraday.
What To Know: The recent rally was supercharged Friday by a new <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46636083/the-secret-ai-powerhouse-winning-big-in-defense-and-beyond">Overweight rating</a> from Piper Sandler, which initiated coverage with a bullish $170 price target. 
This optimism was amplified by CNBC's Jim Cramer, who, after seeing the stock slice through the $150 mark &#8220;like a knife through butter,&#8221; predicted its &#8220;<a href="https://www.benzinga.com/markets/equities/25/07/46657284/palantirs-next-stop-is-200-says-jim-cramer-as-pltr-glides-like-a-knife-through-butter">next stop</a>&#8221; would be $200. This follows continued bullishness from Wedbush analyst Dan Ives, who sees Palantir on a &#8220;golden path to become an AI stalwart.&#8221;
Underpinning the momentum are recent business developments. Last week, the U.S. Army awarded the Anduril-Palantir team a contract for a next-generation command and control prototype, with Palantir's share estimated at $30 million. The company also <a href="https://www.benzinga.com/markets/equities/25/07/46538539/palantir-deloitte-alliance-targets-tech-debt-with-new-ai-powered-operating-system-to-make-america-stronger">recently launched</a> a strategic alliance with Deloitte to accelerate enterprise AI adoption.
The stock's meteoric rise has been remarkable, with shares soaring nearly 500% in the last year. However, despite the high-profile endorsements and contract wins, the broader analyst consensus remains a Sell with an average price target near $81.
Palantir is meanwhile <a href="https://www.benzinga.com/quote/PLTR/earnings">scheduled to report</a> its quarterly earnings next Monday, August 4, where Wall Street analysts are looking for EPS of 13.8 cents on revenue of $939.71 million.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, which provide scores to identify a stock&#8217;s strengths and weaknesses, Palantir scores exceptionally high on key factors. 
The stock boasts a Momentum score of 98.88 and a Growth score of 97.53, indicating very strong recent price performance and a robust growth outlook. Conversely, its Value score is extremely low at 2.39, suggesting the stock is considered expensive relative to its fundamentals. 
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLTR shares are trading flat at $158.22 Monday morning. The stock has a 52-week high of $160.39 and a 52-week low of $21.23.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46640145/how-palantir-tempus-nvidia-backed-recursion-are-disrupting-big-pharma">How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma</a>
<h2 class="wp-block-heading">How To Buy PLTR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Palantir Technologies&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

PLTR

What's Going On With Palantir Technologies Stock?

Raymond James analyst Wilma Burdis initiates coverage on Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Market Perform rating.

ARES

Raymond James Initiates Coverage On Ares Management with Market Perform Rating

Press Releases

CrowdStrike Falcon for AWS Security Incident Response Strengthens Cyber Resilience for AWS Customers

U.S. District Court Dismisses Class Action Lawsuit Against CrowdStrike

CrowdStrike Named a Leader in the 2025 IDC MarketScape: Worldwide Cloud-Native Application Protection Platforms (CNAPP)

Dataminr Appoints Tiffany Buchanan as Chief Financial Officer to Accelerate Strategic Growth and Public Market Readiness

Resilience, CrowdStrike and AWS Work Together to Reduce Cyber Risk for Enterprises

CrowdStrike Named the Leader and Fast Mover in the 2025 GigaOm Radar for Security Information and Event Management

CrowdStrike Brings Agentic AI Security Workflow Integrations and GenAI Protection to AWS Marketplace

CrowdStrike Named a Leader in the 2025 Gartner® Magic Quadrant™ for Endpoint Protection Platforms for Sixth Consecutive Time

CrowdStrike Named the Frost Radar™ Leader in Managed Detection and Response for Second Consecutive Year

CrowdStrike Named a Leader and Fast Mover in the 2025 GigaOm Radar Report for Identity Security Posture Management (ISPM)

Comments

CrowdStrike Holdings

Noticias

Últimas noticias sobre CrowdStrike Holdings (NASDAQ:CRWD) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL